6533b81ffe1ef96bd12781ef
RESEARCH PRODUCT
TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development
Stefan H. E. KaufmannHazel M. DockrellNick DragerMei Mei HoHelen McshaneOlivier NeyrollesTom H. M. OttenhoffBrij PatelDanielle RoordinkFranã§ois SpertiniSteffen StengerJelle TholeFrank A. W. VerreckAnn WilliamsWarwick BrittonJamie TriccasClaudio CounoupasJohan GrootenNull Marie-ange DemoitieMarta RomanoKris HuygenHermann Giresse TimaFrancoise MascartPeter AndersenClaus AagaardDennis ChristensenMorten RuhwaldThomas LindenstromPierre CharneauChristophe GuilhotAntonio PeixotoMartine GilleronIsabelle VergneCamille LochtRoland BroschGenevieve InchauspeStephane Leung Theung LongJanuary WeinerJeroen MaertzdorfNatalie NieuwenhuizenMax BastianStephanie KallertStephen GordonNadia CaccamoDelia GolettiRoberto NisiniSung Jae ShinSang Nae ChoHyejon LeeIno ChoiAlex SigalThomas ScribaGerhard WalzlAndre LoxtonRobert WilkinsonKatalin WilkinsonPere-joan CardonaCris VilaplanaCarlos MartinDessi MarinovaNacho AguiloRuedi AebersoldEtienne CaronDaniel PinschewerGennaro De LiberoClaire Anne SiegristNicolas CollinChristophe Barnier-querPeter SanderJayne SutherlandFrank VerreckTom OttenhoffSimone JoostenKrista Van MeijgaardenMariateresa CoppolaAnnemieke GelukYvonne PerrieMarc BairdMichael LevinMyrsini KaforouSteven SmithHelen FletcherGregory BancroftSimon ClarkSally SharpeIman SattiElena StylianouRachel TannerMartin VordermeierPhilip HogarthDanilo Casimirosubject
TuberculosiImmunologybacille Calmette–Guérin610 Medicine & healthReview[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesTuberculosis; Bacille Calmette-Guérin; Vaccination; Biomarker; Clinical trial; Portfolio management; Discovery[SDV.BC.IC]Life Sciences [q-bio]/Cellular Biology/Cell Behavior [q-bio.CB]Immunology and AllergyBacille Calmette-Guérinbacille Calmette-Guérinbacille Calmette-Guerin2403 Immunology10179 Institute of Medical MicrobiologyBacille Calmette-Guérin; Biomarker; Clinical trial; Discovery; Portfolio management; Tuberculosis; Vaccination; Immunology and Allergy; Immunologyclinical trialvaccination[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human geneticstuberculosis2723 Immunology and Allergy570 Life sciences; biologybiomarkerportfolio managementdiscoverydescription
International audience; TBVAC2020 is a research project supported by the Horizon 2020 program of the European Commission (EC). It aims at the discovery and development of novel tuberculosis (TB) vaccines from preclinical research projects to early clinical assessment. The project builds on previous collaborations from 1998 onwards funded through the EC framework programs FP5, FP6, and FP7. It has succeeded in attracting new partners from outstanding laboratories from all over the world, now totaling 40 institutions. Next to the development of novel vaccines, TB biomarker development is also considered an important asset to facilitate rational vaccine selection and development. In addition, TBVAC2020 offers portfolio management that provides selection criteria for entry, gating, and priority settings of novel vaccines at an early developmental stage. The TBVAC2020 consortium coordinated by TBVI facilitates collaboration and early data sharing between partners with the common aim of working toward the development of an effective TB vaccine. Close links with funders and other consortia with shared interests further contribute to this goal.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2017-10-04 |